GLP1R and chronic kidney disease: Further research is warranted to elucidate the full therapeutic potential of GLP-1 RAs in AS but like many genetic kidney diseases, Alport syndrome patients have been excluded from important clinical trials exploring therapeutics that slow the progression of CKD.